MCID: SWT003
MIFTS: 41

Sweat Gland Disease

Categories: Skin diseases, Endocrine diseases

Aliases & Classifications for Sweat Gland Disease

MalaCards integrated aliases for Sweat Gland Disease:

Name: Sweat Gland Disease 12 15
Sweat Gland Diseases 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1383
ICD10 33 L74 L74.9
ICD9CM 35 705 705.9
MeSH 44 D013543
UMLS 73 C0038986

Summaries for Sweat Gland Disease

MalaCards based summary : Sweat Gland Disease, also known as sweat gland diseases, is related to neuropathy, hereditary sensory and autonomic, type v and askin's tumor, and has symptoms including exanthema, pruritus and increased sweating. An important gene associated with Sweat Gland Disease is NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1), and among its related pathways/superpathways are Apoptosis Modulation and Signaling and Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases. The drugs Oxybutynin and Prazosin have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and testes, and related phenotypes are growth/size/body region and hematopoietic system

Wikipedia : 76 Sweat glands, also known as sudoriferous or sudoriparous glands, from Latin sudor, meaning \'sweat\',... more...

Related Diseases for Sweat Gland Disease

Diseases related to Sweat Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
# Related Disease Score Top Affiliating Genes
1 neuropathy, hereditary sensory and autonomic, type v 10.7 NGF NTRK1
2 askin's tumor 10.7 NGF NTRK1
3 prolactin producing pituitary tumor 10.7 NGF NTRK1
4 conjunctival nevus 10.6 NGF NTRK1
5 anhidrosis 10.4 GLA NGF NTRK1
6 sciatic neuropathy 10.4 NGF TNFRSF1B
7 anal canal squamous cell carcinoma 10.4 NCSTN PSENEN
8 chondromalacia 10.3 IL1RN TNFRSF1B
9 ocular cicatricial pemphigoid 10.3 NGF NTRK1 TNFRSF1B
10 sebaceous gland disease 10.2 NCSTN PSENEN PSTPIP1
11 anterior scleritis 10.1 IL1RN TNFRSF1B
12 skin sarcoidosis 9.9 TNF TNFRSF1B
13 rheumatoid lung disease 9.9 TNF TNFRSF1B
14 chronic gonococcal salpingitis 9.9 TNF TNFRSF1B
15 scleral disease 9.9 TNF TNFRSF1B
16 pustulosis of palm and sole 9.9 TNF TNFRSF1B
17 burning mouth syndrome 9.9 NGF TNF
18 peroneal neuropathy 9.9 TNF TNFRSF1B
19 jejunoileitis 9.9 NGF TNF
20 vulvar vestibulitis syndrome 9.9 IL1RN TNF
21 periodic fever, familial, autosomal dominant 9.8 TNF TNFRSF1B
22 cerebral artery occlusion 9.8 IL1RN TNF
23 acute salpingitis 9.7 TNF TNFRSF1B
24 osteosclerotic myeloma 9.7 IL1RN TNF
25 post-transplant lymphoproliferative disease 9.7 TNF TNFRSF1B
26 chronic salpingitis 9.7 TNF TNFRSF1B
27 panuveitis 9.6 TNF TNFRSF1B
28 familial mediterranean fever 9.6 IL1RN PSTPIP1 TNF
29 pyoderma gangrenosum 9.5 PSTPIP1 TNF
30 tooth agenesis 9.5 EDA EDARADD TNF
31 aseptic meningitis 9.5 IL1RN TNF
32 hypersensitivity reaction type iv disease 9.4 IL1RN TNF TNFRSF1B
33 exanthem 9.4 IL1RN TNF TNFRSF1B
34 joint disorders 9.4 IL1RN TNF
35 bone inflammation disease 9.4 IL1RN TNF TNFRSF1B
36 spondylitis 9.4 IL1RN TNF TNFRSF1B
37 juvenile rheumatoid arthritis 9.4 IL1RN TNF TNFRSF1B
38 pyoderma 9.3 PSTPIP1 TNF
39 behcet syndrome 9.1 IL1RN PSTPIP1 TNF TNFRSF1B
40 arthritis 9.1 IL1RN PSTPIP1 TNF TNFRSF1B
41 hidradenitis suppurativa 8.9 KRT14 NCSTN PSENEN TNF
42 hidradenitis 8.9 KRT14 NCSTN PSENEN TNF
43 hypohidrosis 8.9 COG6 EDA EDARADD GLA KRT14
44 alzheimer disease 8.7 NCSTN NGF NTRK1 PSENEN TNF

Graphical network of the top 20 diseases related to Sweat Gland Disease:



Diseases related to Sweat Gland Disease

Symptoms & Phenotypes for Sweat Gland Disease

UMLS symptoms related to Sweat Gland Disease:


exanthema, pruritus, increased sweating

MGI Mouse Phenotypes related to Sweat Gland Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.06 EDARADD GLA IL1RN KRT14 NCSTN NGF
2 hematopoietic system MP:0005397 10.02 COG6 EDARADD IL1RN KRT14 NCSTN NTRK1
3 cardiovascular system MP:0005385 9.98 TNF TNFRSF1B COG6 GLA IL1RN NCSTN
4 immune system MP:0005387 9.97 COG6 GLA IL1RN KRT14 NCSTN NTRK1
5 integument MP:0010771 9.86 KRT14 NCSTN NGF NTRK1 TNF TNFRSF1B
6 mortality/aging MP:0010768 9.85 NCSTN NGF NTRK1 PSENEN TNF TNFRSF1B
7 nervous system MP:0003631 9.56 COG6 EDARADD GLA NCSTN NGF NTRK1
8 vision/eye MP:0005391 9.23 EDARADD GLA KRT14 NCSTN NGF NTRK1

Drugs & Therapeutics for Sweat Gland Disease

Drugs for Sweat Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5633-20-5 4634
2
Prazosin Approved Phase 4,Not Applicable 19216-56-9 4893
3
Terazosin Approved Phase 4,Not Applicable 63590-64-7 5401
4
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
5
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Mandelic Acids Phase 4,Phase 3,Phase 2,Not Applicable
11 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Renal Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Adrenergic Agents Phase 4,Phase 2,Not Applicable
17 Adrenergic alpha-1 Receptor Antagonists Phase 4,Not Applicable
18 Adrenergic alpha-Antagonists Phase 4,Not Applicable
19 Adrenergic Antagonists Phase 4,Not Applicable
20 Antidepressive Agents Phase 4,Phase 1,Not Applicable
21 Antihypertensive Agents Phase 4,Not Applicable
22 Psychotropic Drugs Phase 4,Phase 1,Not Applicable
23 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 onabotulinumtoxinA Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Anesthetics Phase 4,Phase 1,Not Applicable
31 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
32 Antibiotics, Antitubercular Phase 3,Not Applicable
33
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
34
Ustekinumab Approved, Investigational Phase 2 815610-63-0
35
Infliximab Approved Phase 2 170277-31-3
36
Etanercept Approved, Investigational Phase 2 185243-69-0
37
Liraglutide Approved Phase 2 204656-20-2 44147092
38
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
39
nivolumab Approved Phase 2 946414-94-4
40
Drospirenone Approved Phase 2 67392-87-4 68873
41
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
42 Estradiol valerate Approved, Investigational, Vet_approved Phase 2 979-32-8
43
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
44
Polyestradiol phosphate Approved Phase 2 28014-46-2
45 Dermatologic Agents Phase 2,Phase 1,Not Applicable
46 Bromides Phase 2,Phase 1
47 Pharmaceutical Solutions Phase 2,Phase 1,Not Applicable
48 Analgesics Phase 2
49 Analgesics, Non-Narcotic Phase 2
50 Angiogenesis Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study Completed NCT01310712 Phase 4 Oxybutynin;placebo
2 VASER Treatment of Axillary Hyperhidrosis/Bromidrosis Completed NCT00735293 Phase 4
3 Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin Completed NCT00449683 Phase 4 terazosin
4 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Completed NCT00168480 Phase 4
5 A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis Completed NCT00168415 Phase 4
6 Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) Recruiting NCT02808975 Phase 4 Adalimumab;Placebo
7 Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS Not yet recruiting NCT03221621 Phase 4 Adalimumab Injection
8 Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events. Terminated NCT00669474 Phase 4 Treatment with Botox
9 GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis Completed NCT01128738 Phase 3 GSK1358820;Placebo
10 Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis Completed NCT02553798 Phase 3 DRM04 Topical Wipes
11 Study of DRM04 in Subjects With Axillary Hyperhidrosis Completed NCT02530294 Phase 3 DRM04 Topical Wipes
12 Study of DRM04 in Axillary Hyperhydrosis Completed NCT02530281 Phase 3 DRM04 Topical Wipes
13 Treatment of Hyperhidrosis With Oxybutynin Completed NCT01855256 Phase 3 Oxybutynin;Placebo
14 Liposuction as Treatment for Excessive Axillary Sweat Completed NCT00228072 Phase 2, Phase 3
15 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Completed NCT00168402 Phase 3 Botulinum Toxin Type A
16 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01635764 Phase 3
17 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01468233 Phase 3
18 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Completed NCT01468207 Phase 3
19 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
20 Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs) Recruiting NCT03433859 Phase 3 OnabotulinumtoxinA
21 Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
22 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Active, not recruiting NCT02904902 Phase 3 Adalimumab
23 BTX-A Treatment for Palmar Hyperhidrosis Terminated NCT01262339 Phase 2, Phase 3 BTX-A
24 To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
25 Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis Withdrawn NCT02099695 Phase 3 Oxybutynin;Placebo
26 A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis Completed NCT03024255 Phase 2 BBI-4000 Concentration 1;BBI-4000 Concentration 2;BBI-4000 Concentration 3;Vehicle (Placebo)
27 A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis Completed NCT02682238 Phase 2 BBI-4000, 15%
28 A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects Completed NCT02673619 Phase 2 Umeclidinium;Vehicle
29 Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis Completed NCT02565732 Phase 2
30 Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis Completed NCT02563899 Phase 2 Umeclidinium;Vehicle
31 Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis Completed NCT02479139 Phase 2
32 A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis Completed NCT02336503 Phase 2 BBI-4000 Low Concentration;BBI-4000 Middle Concentration;BBI-4000 High Concentration;Placebo
33 Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis Completed NCT02193139 Phase 2 WL8713, 6 mg;WL8713, 12 mg;WL8713, 18 mg;WL8713, 24 mg;Placebo
34 Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis Completed NCT02129660 Phase 2 Dose 1 of DRM04B;Dose 2 of DRM04B;Dose 1 of DRM04;Dose 2 of DRM04
35 A Dose-Ranging Study of the Effect of DRM04B in Subjects With Axillary Hyperhidrosis Completed NCT02016885 Phase 2 DRM04B, 1.0%;DRM04B, 2.0%;DRM04B, 3.0%;DRM04B, 4.0%
36 Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis Completed NCT01799824 Phase 2
37 A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis Completed NCT01328015 Phase 2 Oxybutynin 5 mg pills
38 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
39 Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
40 Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
41 MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB Completed NCT02643654 Phase 2 MABp1;Placebo
42 Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2
43 A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa Completed NCT01704534 Phase 2 Ustekinumab
44 Anakinra in Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
45 Anakinra as a Treatment for Hydradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
46 Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
47 To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
48 Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
49 Etanercept in Hidradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
50 Etanercept for Treatment of Hidradenitis Completed NCT00107991 Phase 2 etanercept

Search NIH Clinical Center for Sweat Gland Disease

Cochrane evidence based reviews: sweat gland diseases

Genetic Tests for Sweat Gland Disease

Anatomical Context for Sweat Gland Disease

MalaCards organs/tissues related to Sweat Gland Disease:

41
Skin, Neutrophil, Testes

Publications for Sweat Gland Disease

Variations for Sweat Gland Disease

Expression for Sweat Gland Disease

Search GEO for disease gene expression data for Sweat Gland Disease.

Pathways for Sweat Gland Disease

Pathways related to Sweat Gland Disease according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.53 NGF NTRK1 TNF TNFRSF1B
2
Show member pathways
12.31 NCSTN NGF NTRK1 PSENEN
3 12.24 NCSTN NGF NTRK1 PSENEN
4
Show member pathways
12.22 NGF TNF TNFRSF1B
5 11.88 IL1RN NGF TNF
6
Show member pathways
11.36 NGF TNF TNFRSF1B
7
Show member pathways
11.25 NCSTN NGF PSENEN
8 11.02 IL1RN TNF TNFRSF1B
9 10.84 NCSTN PSENEN
10 10.66 NCSTN PSENEN
11 10.64 NGF TNF TNFRSF1B
12
Show member pathways
10.41 NGF NTRK1
13 10.28 EDA EDARADD TNFRSF1B

GO Terms for Sweat Gland Disease

Cellular components related to Sweat Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.43 EDA NCSTN NTRK1 PSENEN TNF TNFRSF1B
2 gamma-secretase complex GO:0070765 8.62 NCSTN PSENEN

Biological processes related to Sweat Gland Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.89 EDA IL1RN TNF TNFRSF1B
2 inflammatory response GO:0006954 9.84 IL1RN PSTPIP1 TNF TNFRSF1B
3 positive regulation of apoptotic process GO:0043065 9.78 NCSTN NGF PSENEN TNF
4 aging GO:0007568 9.76 KRT14 NTRK1 TNFRSF1B
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.74 EDA NTRK1 TNF
6 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.6 NGF TNF
7 membrane protein ectodomain proteolysis GO:0006509 9.58 NCSTN PSENEN
8 positive regulation of Ras protein signal transduction GO:0046579 9.56 NGF NTRK1
9 membrane protein intracellular domain proteolysis GO:0031293 9.55 NCSTN PSENEN
10 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.52 TNF TNFRSF1B
11 neurotrophin TRK receptor signaling pathway GO:0048011 9.51 NGF NTRK1
12 ephrin receptor signaling pathway GO:0048013 9.5 NCSTN NTRK1 PSENEN
13 Notch receptor processing GO:0007220 9.49 NCSTN PSENEN
14 Notch receptor processing, ligand-dependent GO:0035333 9.46 NCSTN PSENEN
15 nerve growth factor signaling pathway GO:0038180 9.43 NGF NTRK1
16 amyloid precursor protein metabolic process GO:0042982 9.4 NCSTN PSENEN
17 positive regulation of programmed cell death GO:0043068 9.37 NTRK1 TNF
18 amyloid precursor protein catabolic process GO:0042987 9.26 NCSTN PSENEN
19 cellular response to nicotine GO:0071316 9.16 NTRK1 TNF
20 amyloid-beta formation GO:0034205 8.96 NCSTN PSENEN
21 tumor necrosis factor-mediated signaling pathway GO:0033209 8.92 EDA EDARADD TNF TNFRSF1B

Molecular functions related to Sweat Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.44 COG6 EDA EDARADD GLA IL1RN KRT14
2 tumor necrosis factor receptor binding GO:0005164 8.96 EDA TNF

Sources for Sweat Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....